Effects of G250 promoter controlled conditionally replicative adenovirus expressing Ki67-siRNA on renal cancer cell

Cancer Science

Volumn 103, Issue 10, 2012, Pages 1880-1888

  Liu, Junjie ^a   Fang, Lin ^a   Cheng, Qian ^a   Li, Liantao ^a   Su, Changqing ^b   Zhang, Baofu ^a   Pei, Dongsheng ^a   Yang, Jie ^a   Li, Wang ^a   Zheng, Junnian ^a  

^a XUZHOU MEDICAL UNIVERSITY   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CARBONATE DEHYDRATASE IX; CONDITIONALLY REPLICATING ADENOVIRUS; CRYSTAL VIOLET; E1A PROTEIN; KI 67 ANTIGEN; SMALL INTERFERING RNA;

ARTICLE; CANCER CELL; CANCER GENE THERAPY; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; PRIORITY JOURNAL; PROMOTER REGION; TRANSGENE; VIRUS CHARACTERIZATION; WESTERN BLOTTING;

ADENOVIRIDAE; ANIMALS; ANTIGENS, NEOPLASM; BLOTTING, WESTERN; CARBONIC ANHYDRASES; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; KIDNEY NEOPLASMS; MICE; MICE, INBRED BALB C; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PROMOTER REGIONS, GENETIC; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84867233383     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2012.02380.x     Document Type: Article

References (26)

1. Ries SJ, Brandts CH. Oncolytic viruses for the treatment of cancer: current strategies and clinical trials. Drug Discov Today 2004; 9: 759-68.
2. Jakubczak JL, Ryan P, Gorziglia M et al. An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy. Cancer Res 2003; 63: 1490-9.
3. Rodriguez R, Schuur ER, Lim HY, Henderson GA, Simons JW, Henderson DR. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res 1997; 57: 2559-63.
4. Hallenbeck PL, Chang YN, Hay C et al. A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. Hum Gene Ther 1999; 10: 1721-33.
5. Ramachandra M, Rahman A, Zou A et al. Re-engineering adenovirus regulatory pathways to enhance oncolytic specificity and efficacy. Nat Biotechnol 2001; 19: 1035-41.
6. Yu DC, Sakamoto GT, Henderson DR. Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy. Cancer Res 1999; 59: 1498-504.
7. Kubo S, Kawasaki Y, Yamaoka N et al. Complete regression of human malignant mesothelioma xenografts following local injection of midkine promoter-driven oncolytic adenovirus. J Gene Med 2010; 12: 681-92.
8. Blok VT, Daha MR, Tijsma O et al. A bispecific monoclonal antibody directed against both the membrane-bound complement regulator CD55 and the renal tumor-associated antigen G250 enhances C3 deposition and tumor cell lysis by complement. J Immunol 1998; 160: 3437-43.
9. Lam JS, Pantuck AJ, Belldegrun AS, Figlin RA. G250: a carbonic anhydrase IX monoclonal antibody. Curr Oncol Rep 2005; 7: 109-15.
10. Luiten RM, Coney LR, Fleuren GJ, Warnaar SO, Litvinov SV. Generation of chimeric bispecific G250/anti-CD3 monoclonal antibody, a tool to combat renal cell carcinoma. Br J Cancer 1996; 74: 735-44.
11. Duan Y, Zheng J, Han S et al. A tumor targeted gene vector modified with G250 monoclonal antibody for gene therapy. J Control Release 2008; 127: 173-9.
12. van den Jongmans W, Oudenalder K, Tiemessen DM et al. Targeting of adenovirus to human renal cell carcinoma cells. Urology 2003; 62: 559-65.
13. Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 1983; 31: 13-20.
14. Beresford MJ, Wilson GD, Makris A. Measuring proliferation in breast cancer: practicalities and applications. Breast Cancer Res 2006; 8: 216.
15. Liu E, Telem DA, Warner RR, Dikman A, Divino CM. The role of Ki-67 in predicting biological behavior of goblet cell carcinoid tumor in appendix. Am J Surg 2011; 202: 400-3.
16. Ali HR, Dawson SJ, Blows FM et al. A Ki67/BCL2 index based on immunohistochemistry is highly prognostic in ER-positive breast cancer. J Pathol 2012; 226: 97-107.
17. Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol 2010; 11: 174-83.
18. Vaisanen A, Kuvaja P, Kallioinen M, Turpeenniemi-Hujanen T. A prognostic index in skin melanoma through the combination of matrix metalloproteinase-2, Ki67, and p53. Hum Pathol 2011; 42: 1103-11.
19. Howell SJ, Wardley AM, Armstrong AC. Re: Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009; 101: 1730.
20. Zheng JN, Ma TX, Cao JY et al. Knockdown of Ki-67 by small interfering RNA leads to inhibition of proliferation and induction of apoptosis in human renal carcinoma cells. Life Sci 2006; 78: 724-9.
21. Zheng JN, Sun YF, Pei DS et al. Anti-Ki-67 peptide nucleic acid affects the proliferation and apoptosis of human renal carcinoma cells in vitro. Life Sci 2005; 76: 1873-81.
22. Toth K, Wold WS. Increasing the efficacy of oncolytic adenovirus vectors. Viruses 2010; 2: 1844-66.
23. O'Shea CC. Viruses - seeking and destroying the tumor program. Oncogene 2005; 24: 7640-55.
24. Doloff JC, Jounaidi Y, Waxman DJ. Dual E1A oncolytic adenovirus: targeting tumor heterogeneity with two independent cancer-specific promoter elements, DF3/MUC1 and hTERT. Cancer Gene Ther 2011; 18: 153-66.
25. Zhang Z, Zou W, Wang J et al. Suppression of tumor growth by oncolytic adenovirus-mediated delivery of an antiangiogenic gene, soluble Flt-1. Mol Ther 2005; 11: 553-62.
26. Liu XY, Qiu SB, Zou WG et al. Effective gene-virotherapy for complete eradication of tumor mediated by the combination of hTRAIL (TNFSF10) and plasminogen k5. Mol Ther 2005; 11: 531-41.